Moreover, Stern et al. reported that DRB1*15 showed an association with lower disease relapse and greater survival in patients treated with HSCT for leukemia or non-Hodgkin lymphoma, but they did not observe any significant difference regarding the incidence of acute GVHD.12 This evidence concerns the gene HLA-DRB1 and acute graft versus host disease.